Autologous natural killer cell therapy for human recurrent malignant glioma

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1861-1871

  Ishikawa, Eiichi ^a,b   Tsuboi, Koji ^a   Saijo, Kaoru ^b   Harada, Hideki ^b   Takano, Shingo ^a   Nose, Tadao ^a   Ohno, Tadao ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Adoptive immunotherapy; Malignant brain tumor; Therapeutic activity

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CELL LINE; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NATURAL KILLER CELL; NEUROTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECURRENT CANCER;

ADULT; AGED; BRAIN NEOPLASMS; COCULTURE TECHNIQUES; FEMALE; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-BETA; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 3242720680     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Gumperz JE and Parham P: The enigma of the natural killer cell. Nature 16: 245-248, 1995.
2. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E and Moretta L: P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 178: 597-604, 1993.
3. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G and Trinchieri G: Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195: 327-333, 2002.
4. Piccioli D, Sbrana S, Melandri E and Valiante NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 195: 335-341, 2002.
5. Barba D, Saris SC, Holder C, Rosenberg SA and Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175-182, 1989.
6. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN and Ransohoff J: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76: 840-852, 1995.
7. Nakagawa K, Kamezaki T, Shibata Y, Tsunoda T, Meguro K and Nose T: Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors. Neurol Med Chir (Tokyo) 35: 22-27, 1995.
8. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
9. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
10. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622-632, 1993.
11. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.
12. Tsuboi K, Saijo K, Ishikawa E, Tsurushima H, Takano S, Morishita Y and Ohno T: Effects of local injection of ex vivo expanded autologous tumor specific T-lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 15: 3294-3302, 2003.
13. Tsurushima H, Liu SQ, Tuboi K, Matsumura A, Yoshii Y, Nose T, Saijo K and Ohno T: Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res 90: 536-545, 1999.
14. Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F and Escudier B: Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. J Biol Response Mod 9: 546-555, 1990.
15. Liu SQ, Saijo K, Todoroki K and Ohno T: Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumor sections. Nat Med 1: 267-271, 1995.
16. Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC and Herberman RB: A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res 48: 3461-3469, 1988.
17. Phillips JH and Lanier LL: A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562. J Exp Med 161: 1464-1482, 1985.
18. Rabinowich H, Sedlmayr P, Herberman RB and Whiteside TL: Increased proliferation, lytic activity and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol 135: 454-470, 1991.
19. Harada H, Saijo K, Watanabe S, Tsuboi K, Nose T, Ishiwata I and Ohno T: Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res 93: 313-319, 2002.
20. Ishiwata I, Ono I, Ishiwata C, Soma M, Nakaguchi T, Ohara K, Hirano M and Ishikawa H: Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo. Exp Pathol 41: 1-9, 1991.
21. Committee of Brain Tumor Registry of Japan: Report of brain tumor registry of Japan (1969-1993). Neurol Med Chir (Tokyo) 40 (suppl): 1-106, 2000.
22. Fine HA, Dear KB, Loeffler JS, Black PM and Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
24. Biron CA, Nguyen KB, Pien GC, Cousens LP and Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17: 189-220, 1999.
25. Duff TA, Borden E, Bay J, Piepmeier J and Sielaff K: Phase II trial of interferon-beta for treatment of recurrent glioblastoma multiforme. J Neurosurg 64: 408-13, 1986.
26. Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, Salcman M and Etcubanas E: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 9: 1945-1949, 1991.
27. Wakabayashi T, Hatano N, Kajita Y, Yoshida T, Mizuno M, Taniguchi K, Ohno T, Nagasaka T and Yoshida J: Initial and maintenance combination treatment with interferon-β, MCNU (Ranimustine) and radiotherapy for patients with previously untreated malignant glioma. J Neuro-Oncol 48: 57-62, 2000.
28. Robertson MJ and Ritz J: Biology and clinical relevance of human natural killer cells. Blood 76: 2421-2438, 1990.
29. Schwarz RE, Vujanovic NL and Hiserodt JC: Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res 49: 1441-1446, 1989.
30. Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW and Hiserodt JC: Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Cancer Res 48: 884-890, 1988.
31. Melder RJ, Brownell AL, Shoup TM, Brownell GL and Jain RK: Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. Cancer Res 53: 5867-5871, 1993.
32. Melder RJ, Salehi HA and Jain RK: Interaction of activated natural killer cells with normal and tumor vessels in cranial windows in mice. Microvasc Res 50: 35-44, 1995.
33. Holladay FP, Heitz T and Wood GW: Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 77: 757-762, 1992.